| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Flupentixol is an antipsychotic neuroleptic drug. It is a thioxanthene, and therefore closely related to the phenothiazines. Its primary use is as a long acting injection given two or three weekly to people with schizophrenia who have a poor compliance with medication and suffer frequent relapses of illness. It is a D1 and D2 receptor antagonist. |
| Indication |
For use in the treatment of schizophrenia and depression |
| Pharmacology |
Flupenthixol is an anxiolytic, antidepressive agent and a mood stabilizer. It inhibits the central monoamine receptors, particularly the dopamine D1 and D2 receptors. Therefore, it increases the amount of serotonin and noradrenaline that control mood and thinking, and improves mood. |
| Toxicity |
LD50=300 mk/kg (Oral in mice); LD50=791 mg/kg (Oral in rats); LD50=87 mk/kg (IV in mice); LD50=37 mg/kg (IV in rats) |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Mainly hepatic |
| Absorption |
Fairly slow and incomplete after oral administration |
| Half Life |
19 to 39 hours |
| Protein Binding |
Highly bound to plasma proteins (>95%) |
| External Links |
|